Acquiring Company
Amgen
Acquired Company
Dark Blue Therapeutics
Thousand Oaks
OxfordBiotechnologyHealth CareBiotechnologyHealth CareDescription
Amgen announced its acquisition of Dark Blue Therapeutics Ltd., a UK-based biotech, for up to $840 million. This acquisition aims to enhance Amgen's oncology pipeline with an innovative treatment for acute myeloid leukemia. The deal will integrate Dark Blue Therapeutics into Amgen's research organization to support early oncology discovery efforts. This strategic move aligns with Amgen's commitment to advancing targeted cancer therapies.
Quick answer
Amgen is acquiring Dark Blue Therapeutics for $840 million, announced January 6, 2026. Amgen is based in Thousand Oaks, California, United States.
- How much did Amgen pay for Dark Blue Therapeutics?
- The reported deal value is $840 million.
- What does Amgen do?
- Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer.
- Where are Amgen and Dark Blue Therapeutics based?
- Amgen is based in Thousand Oaks, California, United States. Dark Blue Therapeutics is based in Oxford, England, United Kingdom.
- Who are the decision-makers at Amgen?
- Fundz holds 2 contacts at Amgen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology and Health Care
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Abbott to acquire Exact Sciences approved by stockholders (February 20, 2026)
- Boston Scientific to acquire Penumbra for $14.5B, $15B (February 19, 2026)
- Danaher acquires Masimo for $9.9 billion, $9.9B (February 18, 2026)
- Sensei Biotherapeutics acquires Faeth Therapeutics (February 18, 2026)
- Waters Corporation acquires Biosciences Solutions (February 9, 2026)
- Medtronic to acquire CathWorks for $585 million, $585M (February 3, 2026)
Who to call at Amgen, and when
When Amgen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Amgen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Amgen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Amgen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Amgen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Dark Blue Therapeutics?
Dark Blue Therapeutics was acquired by Amgen, based in Thousand Oaks. The deal was reported on January 6, 2026. Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. Amgen is publicly traded (AMGN) and operates in Biotechnology.
When did Amgen acquire Dark Blue Therapeutics?
Amgen's acquisition of Dark Blue Therapeutics was reported on January 6, 2026. Amgen announced its acquisition of Dark Blue Therapeutics Ltd., a UK-based biotech, for up to $840 million. This acquisition aims to enhance Amgen's oncology pipeline with an innovative treatment for acute myeloid leukemia. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Dark Blue Therapeutics do?
Dark Blue Therapeutics is an innovative drug discovery biotechnology company based in Oxford, UK. We have assembled a highly experienced team, whose expertise spans the breadth of drug development from discovery to approval. It is privately held, operating in Biotechnology, and is based in Oxford.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.